Kurt W. Evans

4.4k total citations · 1 hit paper
46 papers, 2.9k citations indexed

About

Kurt W. Evans is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kurt W. Evans has authored 46 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 22 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kurt W. Evans's work include Cancer Cells and Metastasis (10 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer-related Molecular Pathways (8 papers). Kurt W. Evans is often cited by papers focused on Cancer Cells and Metastasis (10 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer-related Molecular Pathways (8 papers). Kurt W. Evans collaborates with scholars based in United States, Japan and Germany. Kurt W. Evans's co-authors include Sendurai A. Mani, Brett G. Hollier, Jeffrey M. Rosen, Joseph H. Taube, Jason I. Herschkowitz, Steven J. Werden, Nathalie Sphyris, Venkata Lokesh Battula, Rudy Guerra and Robert A. Weinberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and PLoS ONE.

In The Last Decade

Kurt W. Evans

44 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes

2010 803 citations Joseph H. Taube, Jason I. Herschkowitz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kurt W. Evans United States	21	1.8k	1.7k	842	388	231	46	2.9k
Xinhao Wang China	10	2.3k 1.3×	1.9k 1.1×	1.0k 1.2×	236 0.6×	231 1.0×	21	3.3k
Brett G. Hollier Australia	23	1.2k 0.7×	1.4k 0.8×	754 0.9×	373 1.0×	176 0.8×	46	2.5k
Zhenhe Suo Norway	32	1.3k 0.7×	1.8k 1.1×	872 1.0×	447 1.2×	273 1.2×	107	3.1k
Haili Qian China	31	1.0k 0.6×	1.6k 1.0×	790 0.9×	424 1.1×	264 1.1×	114	2.7k
Kerstin Borgmann Germany	32	1.2k 0.7×	1.8k 1.1×	712 0.8×	497 1.3×	165 0.7×	85	2.7k
Xiaofeng Zheng United States	22	1.6k 0.9×	1.7k 1.0×	917 1.1×	300 0.8×	383 1.7×	52	2.9k
Clémence Thomas France	8	1.6k 0.9×	1.3k 0.8×	675 0.8×	253 0.7×	235 1.0×	10	2.3k
Antonija Kreso Canada	11	1.9k 1.1×	2.2k 1.3×	1.3k 1.5×	304 0.8×	407 1.8×	11	3.7k
Paul A. Berry United Kingdom	14	2.0k 1.2×	1.5k 0.9×	820 1.0×	686 1.8×	258 1.1×	24	3.0k
René Villadsen Denmark	23	1.6k 0.9×	1.3k 0.8×	605 0.7×	271 0.7×	171 0.7×	40	2.5k

Countries citing papers authored by Kurt W. Evans

Since Specialization

Citations

This map shows the geographic impact of Kurt W. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt W. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt W. Evans more than expected).

Fields of papers citing papers by Kurt W. Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt W. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt W. Evans. The network helps show where Kurt W. Evans may publish in the future.

Co-authorship network of co-authors of Kurt W. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt W. Evans. A scholar is included among the top collaborators of Kurt W. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt W. Evans. Kurt W. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Evans, Kurt W., Maria Gabriela Raso, Dhruv Chachad, et al.. (2025). Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations. Molecular Cancer Therapeutics. 24(9). 1402–1414. 1 indexed citations

Meric‐Bernstam, Funda, Erkan Yuca, Kurt W. Evans, et al.. (2024). Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clinical Cancer Research. 31(3). 573–587. 7 indexed citations

DiPeri, Timothy P., Ming Zhao, Kurt W. Evans, et al.. (2023). Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. Journal of Hepatology. 80(2). 322–334. 18 indexed citations

Zhao, Ming, Timothy P. DiPeri, Maria Gabriela Raso, et al.. (2023). Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. npj Breast Cancer. 9(1). 66–66. 17 indexed citations

Saridogan, Turçin, Argun Akçakanat, Ming Zhao, et al.. (2023). Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Scientific Reports. 13(1). 20223–20223. 12 indexed citations

Akçakanat, Argun, Scott Kopetz, Coya Tapia, et al.. (2022). Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific Reports. 12(1). 1248–1248. 7 indexed citations

Shariati, Maryam, Kurt W. Evans, Xiaofeng Zheng, et al.. (2021). Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Oncogene. 40(26). 4425–4439. 17 indexed citations

Li, Dali, Kurt W. Evans, Maria Gabriela Raso, et al.. (2021). Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations. Molecular Cancer Therapeutics. 20(12_Supplement). P058–P058.

Zhao, Ming, Erkan Yuca, Kurt W. Evans, et al.. (2021). First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Research. 23(1). 29–29. 48 indexed citations

10.

Chen, Xian, Angela Alexander, Yufeng Jiang, et al.. (2018). Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clinical Cancer Research. 24(24). 6594–6610. 78 indexed citations

11.

Eckhardt, Bedrich L., Maria Gagliardi, Kurt W. Evans, et al.. (2018). Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies. PLoS ONE. 13(5). e0195932–e0195932. 18 indexed citations

12.

Evans, Kurt W., Erkan Yuca, Argun Akçakanat, et al.. (2017). A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clinical Cancer Research. 23(21). 6468–6477. 48 indexed citations

13.

Yuca, Erkan, Ming Zhao, Kurt W. Evans, et al.. (2017). Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Research. 19(1). 93–93. 46 indexed citations

14.

Kim, Jiha, Pedro Corrêa de Sampaio, Qian Peng, et al.. (2016). Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight. 1(21). e90733–e90733. 24 indexed citations

15.

Blanco, Elvin, Takafumi Sangai, Suhong Wu, et al.. (2014). Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway. Molecular Therapy. 22(7). 1310–1319. 55 indexed citations

16.

Chen, Yu, Manujendra N. Saha, Kurt W. Evans, et al.. (2014). Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia. 29(3). 715–726. 61 indexed citations

17.

Hollier, Brett G., Agata A. Tinnirello, Steven J. Werden, et al.. (2013). FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer. Cancer Research. 73(6). 1981–1992. 220 indexed citations

18.

Battula, Venkata Lokesh, Yuexi Shi, Kurt W. Evans, et al.. (2012). Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. Journal of Clinical Investigation. 122(6). 2066–2078. 234 indexed citations

19.

May, Caitlin D., Nathalie Sphyris, Kurt W. Evans, et al.. (2011). Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Research. 13(1). 202–202. 268 indexed citations

20.

Kolonin, Mikhail G., Kurt W. Evans, Sendurai A. Mani, & Richard H. Gomer. (2011). Alternative origins of stroma in normal organs and disease. Stem Cell Research. 8(2). 312–323. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact